Competitive Intelligence in an Agile World
Adapting intelligence functions to an increasingly complex pharma landscape
This thought piece explores the concept of agile working for the pharma world, delving into the opportunities and challenges that arise for CI teams and managers as working environments adapt to find success in a more dynamic, uncertain, and fast-paced environment.
If agile is the answer, what is the question?
At the heart of pharma stands the monolith that is the clinical trial protocol: three phases; strict regulations governing every aspect of each; enormous quantities of clinical study report data to be captured and translated into coherence. This is the template that pharmaceutical companies have incorporated into every aspect of their decision-making process. Upon these three cascading phased tiers are all pharma workflow decisions made. This structure is immutable, and pharma companies monkey with it at their peril.
Except… recent guidance from the FDA practically begs them to monkey with it. Consider the September 2018 guidance for industry, Adaptive Designs for Clinical Trials of Drugs and Biologics:
“Adaptive designs can provide a variety of advantages over non-adaptive designs. These advantages arise from the fundamental property of clinical trials with an adaptive design: they allow the trial to adjust to information that was not available when the trial began.”1
To anyone familiar with the plethora of modern workflow and productivity systems, that last sentence – allowing the trial to adjust to information not available at the beginning – can only mean one thing:
Somebody at the FDA knows – and cares – about agile.
Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.
Jonas fields questions about his keynote speech, further exploring what strategic intelligence means for pharma and how it can add value.
After decades of clinical research and numerous setbacks, the promise of gene therapy is now much more than a glimmering hope on the horizon. Gene therapy is poised to revolutionize medicine as it presents the opportunity to remove or change the content of an individual’s genetic code in order to potentially treat or cure disease. We explore gene therapy from a few different lenses to give a full picture of where this innovation currently stands.